Diffuse Endothelioma of Bone, Proceedings of the New York Pathological Society, vol.22, pp.95-103, 1921. ,
Descriptive epidemiology of Ewing's tumor-analysis of German patients from (EI)CESS 1980-1997, Klinische Padiatrie, vol.211, pp.271-276, 1999. ,
Report from the Automated Childhood Cancer Information System project, European Journal of Cancer, vol.42, pp.2124-2159, 1978. ,
The neuroectodermal tumor of bone, American Journal of Surgical Pathology, vol.8, pp.885-98, 1984. ,
Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics, American Journal of Surgical Pathology, vol.25, pp.1061-1067, 2001. ,
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation, Proceedings of the National Academy of Sciences USA, vol.90, pp.5752-5758, 1993. ,
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein, Journal of Biological Chemistry, vol.278, pp.15105-15120, 2003. ,
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression, Oncogene, vol.20, pp.3258-65, 2001. ,
Ewing's sarcoma, Lancet Oncology, vol.11, pp.184-92, 2010. ,
Ewing sarcoma cells express RANKL and support osteoclastogenesis, Journal of Pathology, vol.225, pp.195-202, 2011. ,
Molecular mechanisms of tumor-bone interactions in osteolytic metastases, Critical Reviews in Eukaryotic Gene Expression, vol.10, pp.159-78, 2000. ,
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, vol.89, pp.309-328, 1997. ,
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochimica et Biophysica Acta, vol.1704, pp.49-57, 2004. ,
URL : https://hal.archives-ouvertes.fr/inserm-00669006
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-76, 1998. ,
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine and Growth Factor Reviews, vol.15, pp.457-75, 2004. ,
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochemical and Biophysical, Research Communications, vol.247, pp.610-615, 1998. ,
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes and Development, vol.12, pp.1260-1268, 1998. ,
Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases, Cancer, vol.92, pp.460-70, 2001. ,
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis, American Journal of Pathology, vol.163, pp.2021-2052, 2003. ,
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma, Blood, vol.98, pp.3534-3574, 2001. ,
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis, Cancer Research, vol.61, pp.4432-4438, 2001. ,
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption, Cancer Research, vol.67, pp.7308-7326, 2007. ,
Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models, Cancer Gene Therapy, vol.17, pp.387-97, 2010. ,
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, Journal of Biological Chemistry, vol.273, pp.14363-14370, 1998. ,
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells, Cancer Research, vol.62, pp.1619-1642, 2002. ,
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells, Cancer Research, vol.63, pp.912-918, 2003. ,
A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles, Human Gene Therapy, vol.13, pp.1767-75, 2002. ,
Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer, Nucleic Acids Research, vol.32, p.159, 2004. ,
Nonionic amphiphilic block copolymers promote gene transfer to the lung, Human Gene Therapy, vol.16, pp.821-830, 2005. ,
Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles, Human Gene Therapy, vol.16, pp.1318-1342, 2005. ,
Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma, Cancer Research, vol.69, pp.526-562, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01680055
Cellular and molecular mechanisms of action of bisphosphonates, Cancer, vol.88, pp.2961-78, 2000. ,
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, pp.74-86, 2005. ,
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients, Cancer Research, vol.70, pp.7610-7619, 2010. ,
Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient, Journal of Bone and Mineral Research, vol.26, pp.2439-51, 2011. ,
Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology, Journal of Molecular Medicine, vol.79, pp.243-53, 2001. ,
Breast cancer cells interact with osteoblasts to support osteoclast formation, Endocrinology, vol.140, pp.4451-4459, 1999. ,
RANK ligand is a prerequisite for cancer-associated osteolytic lesions, Journal of Pathology, vol.198, pp.228-264, 2002. ,
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochimica et Biophysica Acta, vol.1704, pp.49-57, 2004. ,
URL : https://hal.archives-ouvertes.fr/inserm-00669006
Regulation of cancer cell migration and bone metastasis by RANKL, Nature, vol.440, pp.692-698, 2006. ,
Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice, Journal of Orthopaedic Research, vol.18, pp.967-76, 2000. ,
Osteoprotegerin diminishes advanced bone cancer pain, Cancer Research, vol.61, pp.4038-4085, 2001. ,
Recombinant Osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma, Cancer Research, vol.63, pp.287-296, 2003. ,
Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice, Cancer Research, vol.63, pp.2096-102, 2003. ,
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, Journal of Biological Chemistry, vol.273, pp.14363-14370, 1998. ,
Regulation of osteoprotegerin pro-or anti-tumoral activity by bone tumor microenvironment, Biochimica et Biophysica Acta, vol.1805, pp.17-24, 2010. ,
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women, Journal of Bone and Mineral Research, vol.19, pp.1059-66, 2004. ,
Sun Net al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL, Journal of Bone and Mineral Research, vol.24, pp.182-95, 2009. ,
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases, Expert Opinion on Biological Therapy, vol.9, pp.465-79, 2009. ,
Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma, British Journal of Cancer, vol.96, pp.1716-1738, 2007. ,